First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Béla Ózsvári; Federica Sotgia; Michael P. Lisanti

doi:doi:10.18632/aging.103336

← Back

Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 3. A CSC-based mitochondrial 4-gene signature predicts distant metastasis and tumor recurrence in ER(+) breast cancer patients. To optimize its predictive value, we constructed a short 4-gene signature, which revealed an increase in prognostic value, related to distant metastasis (HR=1.91; P=2.2e-08). This 4-gene signature was also able to predict tumor recurrence in the same patient population (HR=1.68; P=1.2e-15). See also Supplementary Tables 2 and 3 and 3. Therefore, these CSC-based mitochondrial signatures may provide a new prognostic approach for predicting treatment failure in breast cancer patients. DMFS, distant metastasis free survival; RFS, relapse free survival.